Sfoglia per Autore
Comparison of Sequential Testing and Next Generation Sequencing in advanced Lung Adenocarcinoma patients – A single centre experience
2020 Dall'Olio F.G.; Conci N.; Rossi G.; Fiorentino M.; De Giglio A.; Grilli G.; Altimari A.; Gruppioni E.; Filippini D.M.; Di Federico A.; Nuvola G.; Ardizzoni A.
The EGFR exon 19 mutant L747-A750>P exhibits distinct sensitivity to tyrosine kinase inhibitors in lung adenocarcinoma—letter
2020 Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Conci N.; Minari R.; Tiseo M.; Ardizzoni A.
Overcoming Primary Resistance to PD-1 Inhibitor With Anti–PD-L1 Agent in Squamous-Cell NSCLC: Case Report
2020 Gelsomino F.; Di Federico A.; Filippini D.M.; Dall'Olio F.G.; Lamberti G.; Sperandi F.; Balacchi C.; Brocchi S.; Ardizzoni A.
Hyperammonemic encephalopathy during XELOX regimen. Is it capecitabine or oxaliplatin responsible?
2020 Di Federico A.; Nuvola G.; Sisi M.; Lenzi B.; Nobili E.; Campana D.
Targeting DNA damage response and repair genes to enhance anticancer immunotherapy: Rationale and clinical implication
2020 Lamberti G.; Andrini E.; Sisi M.; Di Federico A.; Ricciuti B.
Beyond EGFR, ALK and ROS1: Current evidence and future perspectives on newly targetable oncogenic drivers in lung adenocarcinoma
2020 Lamberti G.; Andrini E.; Sisi M.; Rizzo A.; Parisi C.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report
2020 Mariacristina Di Marco, Riccardo Carloni, Stefania De Lorenzo, Cristina Mosconi, Andrea Palloni, Elisa Grassi, Daria Maria Filippini, Angela Dalia Ricci, Alessandro Rizzo, Alessandro Di Federico, Donatella Santini, Daniela Turchetti, Claudio Ricci, Carlo Ingaldi, Laura Alberici, Francesco Minni, Rita Golfieri, Giovanni Brandi, Riccardo Casadei
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-Analysis
2021 Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Boni L.; Ardizzoni A.
Critical diagnostic delay associated with unusual presentation of hepatocellular carcinoma (Hcc) with orbital metastases: A case report
2021 Filippini D.M.; Di Federico A.; Lenzi B.; Nobili E.; Brocchi S.; Malvi D.; Brandi G.
Should We Test Cancer Susceptibility Genes in Routinely Used Multigene Panels? A Case of Synchronous Lung Adenocarcinoma and Breast Cancer Associated With Germline CHEK2 Mutation
2021 Federico, Alessandro Di; Gelsomino, Francesco; De Biase, Dario; Ardizzoni, Andrea
Nivolumab: an investigational agent for the treatment of biliary tract cancer
2021 Di Federico A.; Rizzo A.; Ricci A.D.; Frega G.; Palloni A.; Tavolari S.; Brandi G.
Hacking pancreatic cancer: Present and future of personalized medicine
2021 Di Federico A.; Tateo V.; Parisi C.; Formica F.; Carloni R.; Frega G.; Rizzo A.; Ricci D.; Di Marco M.; Palloni A.; Brandi G.
STK11/LKB1 and KEAP1 mutations in non-small cell lung cancer: Prognostic rather than predictive?
2021 Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.
PD-1/PD-L1 inhibitor monotherapy or in combination with chemotherapy as upfront treatment for advanced NSCLC with PD-L1 expression ≥ 50%: Selecting the best strategy
2021 Di Federico A.; De Giglio A.; Parisi C.; Gelsomino F.; Ardizzoni A.
Prognostic relevance of pleural invasion for resected NSCLC patients undergoing adjuvant treatments: A propensity score-matched analysis of SEER database
2021 De Giglio A.; Di Federico A.; Gelsomino F.; Ardizzoni A.
Single-agent carboplatin in extensive disease small-cell lung cancer patient with liver failure: A case report within the experience of a single institution
2021 Di Federico A.; Andrini E.; Sisi M.; Nuvola G.; Lamberti G.; Lenzi B.; Nobili E.; Gelsomino F.; Ardizzoni A.
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysis
2021 Di Federico A.; De Giglio A.; Nuvola G.; Deiana C.; Conci N.; Gelsomino F.; Ardizzoni A.
Immune-based combinations for metastatic triple negative breast cancer in clinical trials: current knowledge and therapeutic prospects
2021 Rizzo A.; Ricci A.D.; Lanotte L.; Lombardi L.; Di Federico A.; Brandi G.; Gadaleta-Caldarola G.
Acute kidney injury as a possible immune-related adverse event associated with sustained complete response to BRAF and MEK inhibitors in advanced, V600E-mutated melanoma
2021 Di Federico A.; Filippini D.M.; Sperandi F.; Ardizzoni A.; Melotti B.
Intensive follow-up program and oncological outcomes of 278 biliary tract cancer patients after curative intent surgery: A single-center retrospective experience
2021 Rizzo, A.; Frega, G.; Palloni, A.; Piemontese, A.; Di Federico, A.; Ricci, A.; Carloni, R.; Fabbri, F.; Novelli, M.; Tavolari, S.; Di Marco, M.; Ravaioli, M.; Brandi, G.
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile